Cargando…

Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria

PURPOSE: Phenylketonuria (PKU) is a rare metabolic disorder that requires life-long management to reduce phenylalanine (Phe) concentrations within the recommended range. The availability of pegvaliase (PALYNZIQ™, an enzyme that can metabolize Phe) as a new therapy necessitates the provision of guida...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longo, Nicola, Dimmock, David, Levy, Harvey, Viau, Krista, Bausell, Heather, Bilder, Deborah A., Burton, Barbara, Gross, Christel, Northrup, Hope, Rohr, Fran, Sacharow, Stephanie, Sanchez-Valle, Amarilis, Stuy, Mary, Thomas, Janet, Vockley, Jerry, Zori, Roberto, Harding, Cary O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2018
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752676/ https://www.ncbi.nlm.nih.gov/pubmed/30546086 http://dx.doi.org/10.1038/s41436-018-0403-z

Ejemplares similares

Nutritional status of adults with phenylketonuria on pegvaliase: A 15-month prospective study
por: Viau, Krista, et al.
Publicado: (2023)

Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria
por: Zori, Roberto, et al.
Publicado: (2019)

Discontinuation of Pegvaliase therapy during maternal PKU pregnancy and postnatal breastfeeding: A case report
por: Rohr, Fran, et al.
Publicado: (2020)

Reinstitution of pegvaliase therapy during lactation
por: Rohr, Frances, et al.
Publicado: (2022)

Development of a practical dietitian road map for the nutritional management of phenylketonuria (PKU) patients on pegvaliase
por: Rocha, Júlio César, et al.
Publicado: (2021)

Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
por: Longo, Nicola, et al.
Publicado: (2018)

Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics()
por: Adams, Darius, et al.
Publicado: (2021)

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2021)

A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences
por: Sri Bhashyam, Sumitra, et al.
Publicado: (2019)

Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria
por: Rocha, Júlio César, et al.
Publicado: (2023)

First 1.5 years of pegvaliase clinic: Experiences and outcomes
por: Sacharow, Stephanie, et al.
Publicado: (2020)

Case-control study about the acceptance of Pegvaliase in Phenylketonuria
por: Krämer, Johannes
Publicado: (2020)

Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
por: Patrawala, Meera, et al.
Publicado: (2020)

Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations
por: Cunningham, Amy, et al.
Publicado: (2023)

A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria
por: Hydery, Tasmina, et al.
Publicado: (2019)

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
por: Gupta, Soumi, et al.
Publicado: (2018)

Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data
por: Lah, Melissa, et al.
Publicado: (2022)

Phone-based motivational interviewing to increase self-efficacy in individuals with phenylketonuria
por: Viau, Krista S., et al.
Publicado: (2016)

Retraction notice to “Case-control study about the acceptance of Pegvaliase in Phenylketonuria” Molecular Genetics and Metabolism Reports 22 (2020) 100557.
por: Krämer, Johannes
Publicado: (2021)

Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU)
por: Harding, Cary O.
Publicado: (2019)

A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials
por: Burton, Barbara K., et al.
Publicado: (2021)

Improved attention linked to sustained phenylalanine reduction in adults with early‐treated phenylketonuria
por: Bilder, Deborah A., et al.
Publicado: (2021)

New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
por: Harding, Cary O
Publicado: (2010)

Starting the conversation on gene therapy for phenylketonuria: Current perspectives of patients, caregivers, and advocates
por: Regier, Debra S., et al.
Publicado: (2022)

Continuation of pegvaliase treatment during pregnancy: A case report
por: Boyer, Monica, et al.
Publicado: (2021)

Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation
por: Vonada, Anne, et al.
Publicado: (2023)

Simplified Diet for nutrition management of phenylketonuria: A survey of U.S. metabolic dietitians
por: Hansen, Joyanna, et al.
Publicado: (2020)

Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: A seven-year analysis
por: Waisbren, Susan, et al.
Publicado: (2021)

AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria
por: Richards, Daelyn Y., et al.
Publicado: (2019)

Domino liver transplant from a donor with maple syrup urine disease into a recipient with phenylketonuria
por: Raghu, Vikram K., et al.
Publicado: (2022)

Nutrient intake, body composition, and blood phenylalanine control in children with phenylketonuria compared to healthy controls
por: Sailer, Melissa, et al.
Publicado: (2020)

Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower doses
por: Vucko, Erika R., et al.
Publicado: (2022)

Effects of triheptanoin (UX007) in patients with long‐chain fatty acid oxidation disorders: Results from an open‐label, long‐term extension study
por: Vockley, Jerry, et al.
Publicado: (2020)

Quality of life among parents of children with phenylketonuria (PKU)
por: Fidika, Astrid, et al.
Publicado: (2013)

Phenylketonuria
por: Hudson, Frederick
Publicado: (1969)

Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria
por: Bilder, Deborah A., et al.
Publicado: (2016)

Maternal phenylketonuria syndrome: studies in mice suggest a potential approach to a continuing problem
por: Zeile, William L, et al.
Publicado: (2018)

Overweight and obesity in adult patients with phenylketonuria: a systematic review
por: Tankeu, Aurel T., et al.
Publicado: (2023)

Italian national consensus statement on management and pharmacological treatment of phenylketonuria
por: Burlina, Alberto, et al.
Publicado: (2021)

Dietary amino acid intakes associated with a low-phenylalanine diet combined with amino acid medical foods and glycomacropeptide medical foods and neuropsychological outcomes in subjects with phenylketonuria
por: Stroup, Bridget M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e3egpte4o491tqld1airaclfop